CD39-Targeted Therapies Near Key Milestones, First Approval Projected by 2029Dublin, Jan. 28, 2025 (GLOBE NEWSWIRE) -- The "CD39 Targeted Therapies Clinical Trials, Therapeutic Approaches & Market ...
2monon MSN
Notably, the study found that reducing CD39 expression through shRNA knockdown impaired the cytotoxicity and proliferation of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback